Imunovir

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 18:09, July 5, 2020 by Hip (talk | contribs) (Added ref)

Imunovir or inosine pranobex is an immunostimulant. In a pilot study of sixteen chronic fatigue syndrome patients it increased natural killer cell activity and resulted in a clinical improvement in 60% of patients.[1][2]

References[edit | edit source]

  1. ↑ Diaz-Mitoma, Francisco; Turgonyi, Eva; Kumar, Ashok; Lim, Wilfred; Larocque, Louise; Hyde, Byron M. (January 1, 2003). "Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine®". Journal of Chronic Fatigue Syndrome. 11 (2): 71–95. doi:10.1300/J092v11n02_06. ISSN 1057-3321.
  2. ↑ Patarca-Montero, Roberto (2014). Treatment of Chronic Fatigue Syndrome in the Antiviral Revolution Era: What Does the Research Say?. Routledge. pp. 41–42. ISBN 9781135416294.

Retrieved from "https://me-pedia.org/w/index.php?title=Imunovir&oldid=83107"